Top Medical News
Roshini Claire Anthony, 21 hours ago

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

21 hours ago
Allopurinol dose escalation may effectively lower serum urate to treatment targets in most patients with gout, a study has shown.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. James Yang, Yesterday
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
Yesterday
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
Yesterday
Podcast: Dr Marc Sabatine talks about the FOURIER Outcomes trial which shows lower CV events with the PCSK9 inhibitor evolocumab.
Yesterday
Slideshow: Highlights from the American College of Cardiology 66th Annual Scientific Session (ACC)
Stephen Padilla, Yesterday
The risk of recurrent venous thromboembolism (VTE) is low in women with none or one of the four HERDOO2 criteria (hyperpigmentation, oedema or redness in either leg; D-dimer level ≥250 μg/L while using anticoagulants; obesity with body mass index ≥30; or older age, ≥65 years), a new study reports. These patients can safely discontinue anticoagulants after completing short-term treatment following a first unprovoked VTE event.
Special Reports
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. James Yang, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
Roshini Claire Anthony, 24 Jan 2017

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
16 Dec 2016
ESMYA – Ulipristal acetate 5 mg tab – Zuellig Pharma
Conference Reports
28 Mar 2017
Podcast: Dr Michael Reardon speaks on how the self-expanding TAVR is noninferior to SAVR in intermediate-risk AS patients in the SURTAVI trial.
28 Mar 2017
Podcast: Dr Marc Sabatine talks about the FOURIER Outcomes trial which shows lower CV events with the PCSK9 inhibitor evolocumab.
28 Mar 2017
Slideshow: Highlights from the American College of Cardiology 66th Annual Scientific Session (ACC)
Pearl Toh, 27 Mar 2017
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
Pearl Toh, 25 Mar 2017
Treatment with inclisiran, a siRNA for PCSK9 knockdown, delivers significant and sustained LDL-C lowering in a dose-dependent manner over 6 to 9 months in patients with high cardiovascular (CV) risk, according to the ORION-1* study presented at the ACC.17 Scientific Session held in Washington, DC, US.
Roshini Claire Anthony, 24 Mar 2017

Patients with atrial fibrillation (AF) given digoxin appear to have an elevated risk of mortality, regardless of whether or not they have heart failure, according to a post hoc analysis of the ARISTOTLE* trial presented at the American College of Cardiology (ACC) 66th Scientific Session in Washington DC, US. 

Audrey Abella, 24 Mar 2017
Anticoagulants (ie, novel oral anticoagulants [NOACs], warfarin) were effective in treating subclinical leaflet thrombosis after aortic valve replacement (AVR) compared with dual antiplatelet therapy (DAPT) or mono-antiplatelet therapy (MAPT), according to data presented at the American College of Cardiology’s (ACC) 66th Annual Scientific Session, held in Washington, DC, US.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD